141
9
1
25
Cat. No. | Product Name | Form | Specificity Of Inhibition |
---|---|---|---|
CL0089 |
c-Met/HGFR inhibitor kit
c-Met/HGFR inhibitor kit |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10655 |
c-Met inhibitor 1
3-[(2-甲基-2H-吲唑-5-基)硫基]-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
c-Met inhibitor 1 是一种 c-Met 受体信号通路抑制剂,可用于癌症的治疗,包括胶质母细胞瘤、胃癌和胰腺癌。 | |||
T9990 |
c-Met-IN-15
|
Antibacterial | Microbiology/Virology |
c-Met-IN-15 具有抗菌活性。 | |||
T5349 |
SCR-1481B1
麦他替尼胺丁三醇,c-Met inhibitor 2 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SCR-1481B1 (c-Met inhibitor 2) 能够作用于依赖 Met 激活的癌症,对 VEGFR 具有抑制作用。 | |||
T10653 |
c-met-IN-1
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity. | |||
T10654 |
c-Met-IN-2
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity. | |||
T6154 |
SU11274
Met Kinase Inhibitor,PKI-SU11274 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; CDK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
SU11274 (Met Kinase Inhibitor) 是一种选择性的 Met 抑制剂,IC50值为 10 nM。它对 PGDFRβ,EGFR 或 Tie2 没有抑制作用。 | |||
T2680 |
NVP-BVU972
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
NVP-BVU972 是 Met 选择性抑制剂 (IC50:14 nM) ,它对其它的激酶抑制性较低。 | |||
T67859 |
C-Met inhibitor D9
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
C-Met inhibitor D9 是一种c-Met 激酶抑制剂。 | |||
T7900 |
BAY-474
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
BAY-474 是酪氨酸蛋白激酶 c-MET 抑制剂,能够用于表观遗传学探针。 | |||
T2293 |
SGX-523
|
Raf; p38 MAPK; c-Met/HGFR; Bcr-Abl | Angiogenesis; Cytoskeletal Signaling; MAPK; Tyrosine Kinase/Adaptors |
SGX523 是选择性的和 ATP 竞争性的MET 抑制剂 (IC50:4 nM)。它对 MET 的选择性其它他蛋白激酶高 1000 倍。它具有抗肿瘤特性。 | |||
T6094 |
MK-2461
MK2461 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
MK-2461 是 ATP 竞争性的 c-Met 抑制剂, 平均 IC50 值为 2.5 nM。 | |||
T6095 |
JNJ-38877605
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
JNJ38877605 是 ATP 竞争性 c-Met 抑制剂 (IC50:4 nM),对c-Met 的抑制性比对其它 200 种酪氨酸和丝氨酸-苏氨酸激酶的抑制性高 600 倍。 | |||
T9123 |
DS-1205
|
TAM Receptor | Tyrosine Kinase/Adaptors |
DS-1205b free base 是有效的AXL 激酶选择性抑制剂,IC50为 1.3 nM。它对MER,MET 和TRKA 也有抑制作用,IC50分别为 63、104 和 407 nM。 它可以抑制细胞迁移和肿瘤生长。 | |||
T6117 |
Tivantinib
ARQ 197 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
Tivantinib (ARQ 197) 是一种高选择性c-Met 酪氨酸激酶抑制剂,Ki 为 355 nM。 | |||
T8409 |
SYN1143
RON-IN-1,AMG-1 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
SYN1143 (AMG-1) 是人 RON 和 c-Met 的有效抑制剂。体外激酶测定表明 SYN1143 对人 RON 和 c-Met 的 IC50 分别为 9 和 4 nmol/L。 | |||
T11162 |
EGFR-IN-8
|
EGFR; c-Met/HGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-8 是 EGFR 和 c-Met 的双重抑制剂。 EGFR-IN-8可用于靶向 EGFR TKI 耐药的 NSCLC 的研究。 | |||
T3274 |
S49076
|
FGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
S49076 是一种新型 MET、AXL/MER 和 FGFR1/2/3 高效抑制剂,IC50<20 nM。 | |||
T6378 |
AMG-458
AMG 458 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
AMG-458 是一种口服有活力的c-Met 选择性抑制剂,其对人和小鼠的Ki 分别为 1.2 nM 和 2.0 nM。 | |||
T2419 |
BMS-794833
|
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BMS794833 是一种 VEGFR2 和 Met 的抑制剂,它们的 IC50值分别为 15 和 1.7 nM。 | |||
T6260 |
AMG-208
AMG 208 |
P450; c-Met/HGFR | Metabolism; Tyrosine Kinase/Adaptors |
AMG-208 是一种选择性的、口服有活性的c-Met/RON 双抑制剂,对c-Met 的IC50为 9 nM。他也是CYP3A4抑制剂(IC50:32 μM)。它具有抗癌作用。 | |||
T6128 |
PHA-665752
PHA 665752,PHA665752 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; Bcr-Abl; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PHA-665752 是一种选择性的 ATP 竞争活性位点 c-Met 激酶抑制剂,Ki 为 4 nM,IC50为 9 nM。它对 c-Met 的选择性比一组不同的酪氨酸和丝氨酸苏氨酸激酶高 50 倍。它诱导细胞凋亡和细胞周期阻滞,具有细胞还原性抗肿瘤活性。 | |||
T37596 |
Terevalefim
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Terevalefim 是干细胞生长因子的一种类似物,对c-Met 受体有选择性激活作用。 | |||
T13194 |
CSF1R-IN-2
|
c-Fms; c-Met/HGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
CSF1R-IN-2 是一种口服具有活力的、有效的 SRC,MET 和 c-FMS 抑制剂,它们的 IC50 值分别为 0.12 nM,0.14 nM 和 0.76 nM。 | |||
TQ0041 |
Ningetinib Tosylate
|
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib Tosylate 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T5467 |
SAR125844
SAR125884 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
SAR125844 是高度选择性可逆ATP 竞争性的MET 受体酪氨酸激酶抑制剂,其IC50值为4.2 nM。能抑制细胞中MET 的自磷酸化。 | |||
T5478 |
SRI 31215 TFA
SRI 31215 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
SRI 31215 TFA 是 matriptase、hepsin、肝细胞生长因子激活剂(HGFA)的三重抑制剂,IC50值分别为 0.69 μM、0.65 μM、0.3 μM。它能够阻断 pro-HGF 的活化,模拟 HAI-1/2 的活性。 | |||
T4332 |
c-Kit-IN-1
PDGFR inhibitor 1,DCC-2618 |
c-Met/HGFR; c-Kit | Tyrosine Kinase/Adaptors |
c-Kit-IN-1 (DCC-2618) 是c-Kit 和c-Met 抑制剂(IC50<200 nM)。 | |||
T6907 |
NPS-1034
NPS1034,NPS 1034 |
Apoptosis; c-Met/HGFR; TAM Receptor | Apoptosis; Tyrosine Kinase/Adaptors |
NPS-1034 是一种AXL 和MET 的双重抑制剂,其IC50值分别为 10.3 和 48 nM。 | |||
T15617 |
JNJ-38877618
OMO-1 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
JNJ-38877618 (OMO-1)是一种口服有活性的 Met 激酶选择性抑制剂,其对野生型和突变体的 IC50值分别为2和3 nM。 | |||
T9052 |
XL092
CL-092,JUN04542 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
XL092 (JUN04542) 是一种ATP 竞争性的、口服有效的多受体酪氨酸激酶 (RTKs) 抑制剂,在细胞分析中的MET (IC50:15 nM)、VEGFR2 (IC50:1.6 nM)、AXL (IC50:3.4 nM) 和 MER (IC50:7.2 nM)。它具有抗肿瘤作用,具有用于研究激酶依赖性疾病的潜力。 | |||
T2676 |
PF-04217903
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
PF04217903 是一种高效的、 ATP 竞争性的c-Met 激酶抑制剂(Ki=4.8 nM),相对于 208 个激酶,PF04217903 显示出 1000 倍以上的选择性。它抗血管生成作用。 | |||
T2496 |
(Z)-Semaxinib
SU5416 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
(Z)-Semaxinib (SU5416) 是一种有效的选择性 VEGFR(Flk-1/KDR) 抑制剂 (IC50: 1.23 μM),对 VEGFR 的选择性是 PDGFRβ 的 20 倍,对 FGFR、InsR 和 EGFR 没有抑制作用。 Semaxanib 是一种具有潜在抗肿瘤活性的喹诺酮衍生物。 | |||
T3209 |
AMG-337
AMG337 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
AMG-337 是有效的、ATP 竞争性的、高度选择性的MET 激酶抑制剂,IC50 < 5 nM。 | |||
T5414 |
Glumetinib
SCC244 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Glumetinib (SCC244) 是一种高选择性、ATP 竞争性的、口服具有活力的 c-Met 抑制剂。它对 c-Met 的选择性超过 312 种激酶,包括 c-Met 家族成员 RON 和高度同源的激酶 Axl、Mer、TyrO3。它具有抗肿瘤作用。 | |||
T6517 |
Golvatinib
E-7050,戈伐替尼 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。 | |||
T2699 |
BMS 777607
BMS777607,BMS-777607,BMS 817378 |
c-Met/HGFR; TAM Receptor | Tyrosine Kinase/Adaptors |
BMS 777607 (BMS 817378) 是 Met-related 抑制剂,能够抑制 c-Met (IC50:3.9 nM),Axl (IC50:1.1 nM),Ron (IC50:1.8 nM) 和 Tyro3 (IC50:4.3 nM) 的活性。 | |||
TQ0219 |
MK-8033
|
c-Met/HGFR | Tyrosine Kinase/Adaptors |
MK-8033 是一种新型ATP 竞争性c-Met/Ron 双重抑制剂,对野生型c-Met 的IC50=1 nM,对c-Met N1100Y 的IC50=2.0 nM。 | |||
TQ0021 |
Ningetinib
CT-053,CT053PTSA,宁格替尼 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib (CT-053) 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T10585 |
Bozitinib
CBT-101,PLB-1001 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Bozitinib (PLB-1001) 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子 c-MET 激酶抑制剂,能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。 | |||
T4426 |
CEP-40783
CEP 40783,RXDX-106 |
c-Met/HGFR; TAM Receptor | Tyrosine Kinase/Adaptors |
CEP-40783 (RXDX-106) 是一种有口服活性的,高效的,选择性的 AXL (IC50:7 nM) 和 c-Met (IC50:12 nM) 抑制剂。 | |||
T3455 |
Merestinib
LY2801653 |
Discoidin Domain Receptor (DDR); FLT; c-Met/HGFR; ROS; ROS Kinase | Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Merestinib (LY2801653) 是一种有效的口服生物可利用的具有抗肿瘤活性的c-Met 抑制剂。 | |||
TQ0210 |
Savolitinib
AZD-6094,Volitinib,沃利替尼,赛沃替尼,HMPL-504 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Savolitinib (Volitinib) 是一种高效选择性、口服生物利用度c-Met 抑制剂,能够抑制 c-Met (IC50:5 nM)和 p-Met (IC50:3 nM)。它以 ATP 竞争的方式选择性结合并抑制 c-Met 的激活,破坏 c-Met 信号转导途径,具有抗肿瘤作用。 | |||
T1661 |
Crizotinib
PF-02341066,克唑替尼 |
c-Met/HGFR; ROS; ALK; Autophagy; ROS Kinase | Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Crizotinib (PF-02341066) 是 c-MET 和 ALK 受体的 ATP 竞争性小分子酪氨酸激酶抑制剂,IC50为 8和20 nM。在细胞的实验中,它抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化。它也是 ROS1抑制剂。它有肿瘤生长抑制作用。 | |||
TP2382 |
Gastrin hexapeptide
Tyr-gly-trp-met-asp-phe-NH2,Gastrin C-terminal hexapeptide |
||
Gastrin hexapeptide is a hexapeptide from porcine antral mucosa. | |||
T8825 |
Capmatinib 2HCl.H2O
INCB28060 2HCl.H2O,INC-280 2HCl.H2O,NVP-INC280 2HCl.H2O |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) 是一种具有潜在抗肿瘤活性的原癌基因 c-Met (HGFR) 的口服生物可利用抑制剂。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
T1963 |
Capmatinib
NVP-INC280,INC-280,卡马替尼,INCB28060 |
Apoptosis; c-Met/HGFR | Apoptosis; Tyrosine Kinase/Adaptors |
Capmatinib (INCB28060) 是一种具有口服活性的,选择性的,ATP 竞争性的c-Met 激酶抑制剂,IC50值为0.13 nM。它有效抑制 c-Met 依赖性肿瘤细胞的增殖和迁移,可诱导细胞凋亡,有抗肿瘤活性。 | |||
T2516 |
Amuvatinib
MP470,HPK 56 |
Apoptosis; FLT; c-Met/HGFR; c-RET; DNA/RNA Synthesis; PDGFR; c-Kit | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Amuvatinib (MP470) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-Kit,PDGFRα,Flt3,c-Met 和 c-Ret 具有活性。它还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复,具有抗肿瘤活性。 | |||
T6351 |
MGCD-265 analog
MGCD-265,Glesatinib |
Apoptosis; VEGFR; c-Met/HGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
MGCD-265 analog (Glesatinib) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂,具有抗肿瘤活性,对 c-Met 和 VEGFR2 的 IC50 分别为 29 nM 和 10 nM。 | |||
T8416 |
Capmatinib xHCl
INCB28060,Capmatinib hydrochloride(free base),INC280 |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Capmatinib xHCl (INCB28060) 是一种有效的、口服活性的、选择性的和 ATP 竞争性 c-Met 激酶抑制剂,有效地阻断体外激酶活性 (IC50 = 0.13 nM) 以及在细胞中的组成型或 HGF 刺激活性(IC50 值范围从 0.3 到1.1纳米)。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13108 |
Pamufetinib
H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Pamufetinib (TAS-115) 是VEGFR 和c-Met/HGFR 抑制剂,能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。 | |||
T5656 |
(±)-Norcantharidin
Endothall anhydride,去甲斑蝥素,Norcantharidin |
EGFR; c-Met/HGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
(±)-Norcantharidin (Endothall anhydride) 是一种人类结肠癌中 c-Met 和 EGFR 的双重抑制剂,可研究抗癌,具有抗血管生成活性。 | |||
T2894 |
Norcantharidin
Norcantharadine,去甲斑蝥素,Endothall anhydride |
EGFR; c-Met/HGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Norcantharidin (Norcantharadine) 是一种合成的抗癌化合物,是人类结肠癌中 c-Met 和 EGFR 的双重抑制剂。 | |||
T3S0335 |
Soyasaponin Bb
Soyasaponin I,大豆皂苷Bb |
NF-κB; Caspase | Apoptosis; NF-κB; Proteases/Proteasome |
Soyasaponin Bb (Soyasaponin I) 是一种分离自菜豆科中的大豆皂苷,可用作醛糖还原酶差异抑制剂。 | |||
T5S1331 |
Herbacetin
|
c-Met/HGFR; Akt | Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Herbacetin 是一种亚麻籽中的天然类黄酮,具有多种药理活性,如抗氧化、抗炎、抗癌作用。 它是鸟氨酸脱羧酶Ornithine decarboxylase (ODC)变构抑制剂,能够直接与 ODC 上的 Asp44,Asp243 和 Glu384 结合。其中鸟氨酸脱羧酶是多胺生物合成中的限速酶。 | |||
TJS0339 |
Coumarin-3-carboxylic acid
香豆素-3-羧酸,3-Carboxycoumarin |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Coumarin-3-carboxylic acid (3-Carboxycoumarin) 是一种合成香豆素的重要起始化合物。其中香豆素是具有多种生物活性的天然产物。它的镧系复合物对 K-562 细胞具有抗增殖活性。 | |||
T16035 |
Meleagrin
|
Others | Others |
Meleagrin, a roquefortine C-derived alkaloid produced by Penicillium fungi, serves as both a class of FabI inhibitors and a lead c-Met inhibitory entity for controlling c-Met-dependent metastatic and invasive breast malignancies. It exhibits antimicrobial and anti-proliferative activities. | |||
TN1549 |
Damnacanthal
丹宁卡 |
IL Receptor; Akt; Syk | Angiogenesis; Cytoskeletal Signaling; Immunology/Inflammation; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Damnacanthal possesses anti-cancer, immunomodulatory, antinociceptive and anti-inflammatory actions, it can treat or prevent hepatocellular carcinoma through its inhibitory effects on the HGF/c-Met axis. | |||
TN4023 |
Eucalyptin
|
Antifection | Microbiology/Virology |
Eucalyptin has antioxidant and antimicrobial properties, it exhibits potent antimicrobial activities against seven micro-organisms with minimum inhibitory concentrations (MIC) ranging from 1.0 to 31 mg/L. Eucalyptin A exhibits potent inhibition on HGF/c-M |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01896 |
HGFR/c-Met Protein, Mouse, Recombinant (His)
MET proto-oncogene, rece... |
Mouse | HEK293 Cells |
HGFR/c-Met Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 102 kDa and the accession number is EDL13881.1. | |||
TMPY-01296 |
HGFR/c-Met Protein, Human, Recombinant (His)
AUTS9,MET proto-oncogene, rec... |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103 kDa and the accession number is A0A024R759. | |||
TMPK-00499 |
HGFR/c-Met Protein, Cynomolgus, Recombinant (His)
MET,oncogene MET |
Cynomolgus | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPK-00457 |
HGFR/c-Met Protein, Human, Recombinant (His & Avi)
cMET,Met (c... |
Human | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPY-01895 |
HGFR/c-Met Protein, Mouse, Recombinant (hFc)
c-Met,AI838057,MET |
Mouse | HEK293 Cells |
HGFR/c-Met Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128 kDa and the accession number is A4FUV6. | |||
TMPY-00718 |
HGFR/c-Met Protein, Human, Recombinant (His & hFc)
DFNB97,RCCP2,AUTS9,MET p... |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His & hFc) is expressed in HEK293 mammalian cells with His and hFc tag. The predicted molecular weight is 129.5 kDa and the accession number is A0A024R759. | |||
TMPY-05441 |
HGFR/c-Met Protein, Human, Recombinant (hFc)
HGFR,DFNB97,RCCP2,AUTS9,c- |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.4 kDa and the accession number is A0A024R759. | |||
TMPY-05607 |
HGFR/c-Met Protein, Human, Recombinant (His & Avi), Biotinylated
MET proto-oncogene, rece... |
Human | HEK293 Cells |
HGFR/c-Met Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 104.9 kDa and the accession number is A0A024R759. | |||
TMPY-04379 |
HGFR/c-Met Protein, Human, Recombinant (aa 956-1390, His & GST)
MET proto-oncogene, rece... |
Human | Baculovirus Insect Cells |
HGFR/c-Met Protein, Human, Recombinant (aa 956-1390, His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 76.8 kDa and the accession number is P08581-1. | |||
TMPJ-00415 |
HGFR/c-Met Protein, Human, Recombinant (aa 25-932, His & Avi), Biotinylated
SF receptor,HGF receptor,Scatter ... |
Human | HEK293 Cells |
Hepatocyte growth factor receptor (HGF R) is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. Mature HGF R is a disulfide-linked dimer composed of a 50 kDa extracellular α chain and a 145 kDa transmembrane β chain. Proteolysis and alternate splicing generate additional forms of human HGF R which either lack of the kinase domai... | |||
TMPY-00548 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His)
MET proto-oncogene, rece... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103.1 kDa and the accession number is G7MM61. | |||
TMPY-03581 |
HGFR/c-Met Protein, Rat, Recombinant (hFc)
MET proto-oncogene, rece... |
Rat | HEK293 Cells |
HGFR/c-Met Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.1 kDa and the accession number is Q2IBC7. | |||
TMPY-02068 |
HGFR/c-Met Protein, Canine, Recombinant (His)
MET proto-oncogene, rece... |
Canine | HEK293 Cells |
HGFR/c-Met Protein, Canine, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103 kDa and the accession number is Q75ZY9. | |||
TMPY-00634 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant
MET proto-oncogene, rece... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 102.3 kDa and the accession number is G7MM61. | |||
TMPY-06657 |
HGFR/c-Met Protein, Rat, Recombinant (His)
MET proto-oncogene, rece... |
Rat | HEK293 Cells |
HGFR/c-Met Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 102.53 kDa and the accession number is XP_006236191.1. | |||
TMPY-00546 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (hFc)
MET proto-oncogene, rece... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 128.3 kDa and the accession number is G7MM61. | |||
TMPY-06278 |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His), Biotinylated
MET proto-oncogene, rece... |
Cynomolgus,Rhesus | HEK293 Cells |
HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 103.1 kDa and the accession number is NP_001162100.2. | |||
TMPJ-00375 |
HGF Protein, Human, Recombinant (His)
Scatter factor,Hepatocyte growth ... |
Human | HEK293 Cells |
HGF, is a pleiotropic protein in the Plasminogen subfamily of S1 peptidases and contains 4 kringle domains, 1 PAN domain and 1 peptidase S1 domain. HGF is secreted as an inactive 728 amino acid (aa) single chain propeptide. It is cleaved after the fourth Kringle domain by a serine protease to form bioactive disulfide-linked HGF with a 60 kDa alpha and 30 kDa beta chain. HGF binds heparan-sulfate proteoglycans and the widely expressed receptor tyrosine kinase, HGF R/c-MET. HGF regulates epithelia... | |||
TMPK-00369 |
HGF Protein, Human, Recombinant (hFc)
HGF,F-TCF,HGFB,SF,F-TCFB,肝细胞生长因子,DFNB39,He... |
Human | HEK293 Cells |
Hepatocyte growth factor (HGF) is an important component of the pathophysiology of IR, with increased levels in most common IR conditions, including obesity. HGF has a role in the metabolic flux of glucose in different insulin sensitive cell types; plays a key role in β-cell homeostasis; and is capable of modulating the inflammatory response.HGF plays a central role in these metabolic disorders,HGF levels could be employed as a biomarker for disease status/progression, and HGF/c-Met signaling pa... | |||
TMPY-02028 |
RON/CD136 Protein, Human, Recombinant (His)
CD136,macrophage stimulating 1 rec |
Human | HEK293 Cells |
The tyrosine kinase receptor, macrophage-stimulating 1 receptor (MST1R), a c-met-related tyrosine kinase, also known as the Ron receptor or CD136, controls cell survival and motility programs related to invasive growth. As the tyrosine kinase receptor is comprised of an extracellular domain, MST1R protein contains the ligand-binding pocket and an intracellular region where the kinase domain is located. MST1R signaling may be involved in the regulation of macrophage and T-lymphocyte activation in... | |||
TMPJ-00891 |
Kallikrein 2/KLK2 Protein, Human, Recombinant (His)
hGK-1,Kallikrein-2,Tissue Kallikrein-2,KLK2,Glandular Kallik... |
Human | HEK293 Cells |
Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. KLK2 ... | |||
TMPJ-01184 |
CPA4 Protein, Mouse, Recombinant (His)
CPA4,Carboxypeptidase A4 |
Mouse | HEK293 Cells |
Carboxypeptidase A4 (CPA4) is a member of the peptidase M14 family. CPA4 is metalloprotease that could be involved in the histone hyperacetylation pathway. CPA4 binds one zinc ion per subunit and could catalyze to release of a C-terminal amino acid, with preference for -Phe, -Leu, -Ile, -Met, -Tyr and -Val.They have distinct expression patterns and different specificities for example, preferentially cleaving aromatic (carboxypeptidase As) or basic (carboxypeptidase Bs) residues. Several, such as... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |